Development of bone and cartilage in tissue-engineered human middle phalanx models.
Human middle phalanges were tissue-engineered with midshaft scaffolds of poly(L-lactide-epsilon-caprolactone) [P(LA-CL)], hydroxyapatite-P(LA-CL), or beta-tricalcium phosphate-P(LA-CL) and end plate scaffolds of bovine chondrocyte-seeded polyglycolic acid. Midshafts were either wrapped with bovine periosteum or left uncovered. Constructs implanted in nude mice for up to 20 weeks were examined for cartilage and bone development as well as gene expression and protein secretion, which are important in extracellular matrix (ECM) formation and mineralization. Harvested 10- and 20-week constructs without periosteum maintained end plate cartilage but no growth plate formation. They also consisted of chondrocytes secreting type II collagen and proteoglycan, and they were composed of midshaft regions devoid of bone. In all periosteum-wrapped constructs at like times, end plate scaffolds held chondrocytes elaborating type II collagen and proteoglycan and cartilage growth plates resembling normal tissue. Chondrocyte gene expression of type II collagen, aggrecan, and bone sialoprotein varied depending on midshaft composition, presence of periosteum, and length of implantation time. Periosteum produced additional cells, ECM, and mineral formation within the different midshaft scaffolds. Periosteum thus induces midshaft development and mediates chondrocyte gene expression and growth plate formation in cartilage regions of phalanges. This work is important for understanding developmental principles of tissue-engineered phalanges and by extension those of normal growth plate cartilage and bone.
Wada
Yoshitaka
Y
Department of Integrative Medical Sciences, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, Ohio 44272, USA.
Enjo
Mitsuhiro
M
Isogai
Noritaka
N
Jacquet
Robin
R
Lowder
Elizabeth
E
Landis
William J
WJ
D053674:Aggrecans / Q000235:genetics / Q000378:metabolism; D000818:Animals; D001846:Bone Development / Q000187:drug effects / Q000502:physiology*; D002130:Calcium Phosphates / Q000494:pharmacology; D002356:Cartilage / Q000166:cytology / Q000187:drug effects / Q000254:growth & development*; D002417:Cattle; D019902:Chondrocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D024043:Collagen Type II / Q000235:genetics / Q000378:metabolism; D017886:Durapatite / Q000494:pharmacology; D050278:Finger Phalanges / Q000166:cytology / Q000000981:diagnostic imaging / Q000187:drug effects / Q000502:physiology*; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D020007:Implants, Experimental; D058574:Integrin-Binding Sialoprotein; D051379:Mice; D008855:Microscopy, Electron, Scanning; D008954:Models, Biological; D016612:Paraffin Embedding; D010521:Periosteum / Q000166:cytology / Q000187:drug effects; D011091:Polyesters / Q000494:pharmacology; D011859:Radiography; D012795:Sialoglycoproteins / Q000235:genetics / Q000378:metabolism; D023822:Tissue Engineering / Q000379:methods*; D054457:Tissue Scaffolds / Q000737:chemistry
D053674:Aggrecans; D002130:Calcium Phosphates; D024043:Collagen Type II; C546871:IBSP protein, human; C546872:Ibsp protein, mouse; D058574:Integrin-Binding Sialoprotein; D011091:Polyesters; D012795:Sialoglycoproteins; C485817:beta-tricalcium phosphate; C062968:lactide-caprolactone copolymer; D017886:Durapatite